Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Xencor, Inc. (XNCR) Guidance & Earnings Results

On 2026-07-29 Xencor, Inc. reaffirmed guidance: "Cash runway extended through…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

XNCRXencor, Inc.Follow XNCR — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
1.9B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
9 Nov, in 16 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
29 Jul 26ReaffirmedCash runway extended through 2028
6 May 26ReaffirmedCash guidance $380-400M year-end 2026 · full year
25 Feb 26—FY2026 cash guidance $400-430M; sufficient cash through 2028 · full year
8 Jan 26ReaffirmedCash runway through 2028 · full year
6 Aug 25ReaffirmedFY2025 cash, cash equivalents and marketable debt securities $555-585M · full year

Xencor, Inc. — questions

What guidance did Xencor, Inc. give?
On 2026-07-29: "Cash runway extended through 2028"
When does Xencor, Inc. report earnings?
Xencor, Inc.'s next earnings report is expected on 2026-11-09.

Every figure on this page comes from Xencor, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.